Sensitization of intracellular salmonella enterica serovar Typhimurium to Aminoglycosides in vitro and in vivo by a host-targeted antimicrobial agent

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7375-7382

  Lo, Jung Hsin ^a   Kulp, Samuel K ^b   Chen, B Ching Shih ^b,c   Chiua, Hao Chieh ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b OHIO STATE UNIVERSITY   (United States)

^c INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; AR 12; GENTAMICIN; KANAMYCIN; STREPTOMYCIN; UNCLASSIFIED DRUG; 2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; AMINOGLYCOSIDE; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; SALMONELLA TYPHIMURIUM; SENSITIZATION; ANIMAL; BAGG ALBINO MOUSE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; GROWTH, DEVELOPMENT AND AGING; INTRAPERITONEAL DRUG ADMINISTRATION; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; SALMONELLA INFECTIONS, ANIMAL; SURVIVAL;

AMIKACIN; AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GENTAMICINS; INJECTIONS, INTRAPERITONEAL; KANAMYCIN; MACROPHAGES; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PYRAZOLES; SALMONELLA INFECTIONS, ANIMAL; SALMONELLA TYPHIMURIUM; STREPTOMYCIN; SULFONAMIDES; SURVIVAL ANALYSIS;

EID: 84912121162     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03778-14     Document Type: Article

References (37)

1. Magnet S, Blanchard JS. 2005. Molecular insights into aminoglycoside action and resistance. Chem. Rev. 105:477-498. http://dx.doi.org/10.1021 /cr0301088.
2. Wentworth BB. 1973. Use of gentamicin in isolation of subgroup-a Chlamydia. Antimicrob. Agents Chemother. 3:698-702. http://dx.doi.org/10 .1128/AAC.3.6.698.
3. White LA, Hall HE, Tzianabos T, Chappell WA. 1976. Effect of gentamicin on growth of viral, chlamydial, and rickettsial agents in mice and embryonated eggs. Antimicrob. Agents Chemother. 10:344-346.
4. Seral C, Van Bambeke F, Tulkens PM. 2003. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob. Agents Chemother. 47:2283-2292. http://dx.doi.org/10.1128/AAC.47.7.2283-2292.2003.
5. Rodgers FG, Tzianabos AO, Elliott TS. 1990. The effect of antibiotics that inhibit cell-wall, protein, and DNA synthesis on the growth and morphology of Legionella pneumophila. J. Med. Microbiol. 31:37-44. http: //dx.doi.org/10.1099/00222615-31-1-37.
6. Kihlström E, Andaker L. 1985. Inability of gentamicin and fosfomycin to eliminate intracellular Enterobacteriaceae. J. Antimicrob. Chemother. 15: 723-728. http://dx.doi.org/10.1093/jac/15.6.723.
7. Lutwyche P, Cordeiro C, Wiseman DJ, St-Louis M, Uh M, Hope MJ, Webb MS, Finlay BB. 1998. Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes. Antimicrob. Agents Chemother. 42:2511-2520.
8. Gnanadhas DP, Ben Thomas M, Elango M, Raichur AM, Chakravortty D. 2013. Chitosan-dextran sulphate nanocapsule drug delivery system as an effective therapeutic against intraphagosomal pathogen Salmonella. J. Antimicrob. Chemother. 68:2576-2586. http://dx.doi.org/10.1093/jac /dkt252.
9. Coburn B, Grassl GA, Finlay BB. 2007. Salmonella, the host and disease: a brief review. Immunol. Cell Biol. 85:112-118. http://dx.doi.org/10.1038 /sj.icb.7100007.
10. Crump JA, Luby SP, Mintz ED. 2004. The global burden of typhoid fever. Bull. World Health Organ. 82:346-353.
11. Majowicz SE, Musto J, Scallan E, Angulo FJ, Kirk M, O'Brien SJ, Jones TF, Fazil A, Hoekstra RM, International Collaboration on Enteric Disease 'Burden of Illness' Studies. 2010. The global burden of nontyphoidal Salmonella gastroenteritis. Clin. Infect. Dis. 50:882-889. http: //dx.doi.org/10.1086/650733.
12. Haraga A, Ohlson MB, Miller SI. 2008. Salmonellae interplay with host cells. Nat. Rev. Microbiol. 6:53-66. http://dx.doi.org/10.1038/nrmicro1788.
13. Watson KG, Holden DW. 2010. Dynamics of growth and dissemination of Salmonella in vivo. Cell. Microbiol. 12:1389-1397. http://dx.doi.org/10 .1111/j.1462-5822.2010.01511.x.
14. Steele-Mortimer O. 2008. The Salmonella-containing vacuole: moving with the times. Curr. Opin. Microbiol. 11:38-45. http://dx.doi.org/10 .1016/j.mib.2008.01.002.
15. Menashe O, Kaganskaya E, Baasov T, Yaron S. 2008. Aminoglycosides affect intracellular Salmonella enterica serovars typhimurium and virchow. Antimicrob. Agents Chemother. 52:920-926. http://dx.doi.org/10 .1128/AAC.00382-07.
16. st century: promises and shortcomings. Clin. Microbiol. Infect. 17:959-963. http://dx.doi.org /10.1111/j.1469-0691.2011.03552.x.
17. Crump JA, Mintz ED. 2010. Global trends in typhoid and paratyphoid fever. Clin. Infect. Dis. 50:241-246. http://dx.doi.org/10.1086/649541.
18. Chiu HC, Kulp SK, Soni S, Wang D, Gunn JS, Schlesinger LS, Chen CS. 2009. Eradication of intracellular Salmonella enterica serovar Typhimurium with a small-molecule, host cell-directed agent. Antimicrob. Agents Chemother. 53:5236-5244. http://dx.doi.org/10.1128/AAC.00555-09.
19. Chiu HC, Soni S, Kulp SK, Curry H, Wang D, Gunn JS, Schlesinger LS, Chen CS. 2009. Eradication of intracellular Francisella tularensis in THP-1 human macrophages with a novel autophagy inducing agent. J. Biomed. Sci. 16:110. http://dx.doi.org/10.1186/1423-0127-16-110.
20. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, Shaw YJ, Kulp SK, Chen CS. 2004. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 64:4309-4318. http://dx.doi.org/10.1158/0008-5472 .CAN-03-4063.
21. th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
22. Karasawa T, Wang Q, David LL, Steyger PS. 2010. CLIMP-63 is a gentamicin-binding protein that is involved in drug-induced cytotoxicity. Cell Death Dis. 1:e102. http://dx.doi.org/10.1038/cddis.2010.80.
23. Barcia-Macay M, Seral C, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. 2006. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob. Agents Chemother. 50:841-851. http://dx.doi .org/10.1128/AAC.50.3.841-851.2006.
24. Drevets DA, Canono BP, Leenen PJ, Campbell PA. 1994. Gentamicin kills intracellular Listeria monocytogenes. Infect. Immun. 62:2222-2228.
25. Maurin M, Raoult D. 2001. Use of aminoglycosides in treatment of infections due to intracellular bacteria. Antimicrob. Agents Chemother. 45:2977-2986. http://dx.doi.org/10.1128/AAC.45.11.2977-2986.2001.
26. Bonventre PF, Imhoff JG. 1970. Uptake of h-dihydrostreptomycin by macrophages in culture. Infect. Immun. 2:89-95.
27. Finlay BB, Hancock RE. 2004. Can. innate immunity be enhanced to treat microbial infections? Nat. Rev. Microbiol. 2:497-504. http://dx.doi.org /10.1038/nrmicro908.
28. Kuijl C, Savage NDL, Marsman M, Tuin AW, Janssen L, Egan DA, Ketema M, van den Nieuwendijk R, van den Eeden SJF, Geluk A, Poot A, van der Marel G, Beijersbergen RL, Overkleeft H, Ottenhoff THM, Neefjes J. 2007. Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature 450:725-730. http://dx.doi.org/10 .1038/nature06345.
29. Schwegmann A, Brombacher F. 2008. Host-directed drug targeting of factors hijacked by pathogens. Sci. Signal. 1:re8. http://dx.doi.org/10.1126 /scisignal.129re8.
30. Zumla A, Nahid P, Cole ST. 2013. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 12: 388-404. http://dx.doi.org/10.1038/nrd4001.
31. Wu X, Lin M, Li Y, Zhao X, Yan F. 2009. Effects of DMEM and RPMI 1640 on the biological behavior of dog periosteum-derived cells. Cytotechnology 59:103-111. http://dx.doi.org/10.1007/s10616-009-9200-5.
32. Barry AL, Reller LB, Miller GH, Washington JA, Schoenknect FD, Peterson LR, Hare RS, Knapp C. 1992. Revision of standards for adjusting the cation content of Mueller-Hinton broth for testing susceptibility of Pseudomonas aeruginosa to aminoglycosides. J. Clin. Microbiol. 30:585-589.
33. Sweileh WM. 2009. A prospective comparative study of gentamicin- and amikacin-induced nephrotoxicity in patients with normal baseline renal function. Fundam. Clin. Pharmacol. 23:515-520. http://dx.doi.org/10 .1111/j.1472-8206.2009.00702.x.
34. Newman MJ, Frimpong E, Donkor ES, Opintan JA, Asamoah-Adu A. 2011. Resistance to antimicrobial drugs in Ghana. Infect. Drug Resist. 4:215-220. http://dx.doi.org/10.2147/IDR.S21769.
35. Rotimi VO, Jamal W, Pal T, Sonnevend A, Dimitrov TS, Albert MJ. 2008. Emergence of multidrug-resistant Salmonella spp. and isolates with reduced susceptibility to ciprofloxacin in Kuwait and the United Arab Emirates. Diagn. Microbiol. Infect. Dis. 60:71-77. http://dx.doi.org/10 .1016/j.diagmicrobio.2007.07.007.
36. Manchanda V, Bhalla P, Sethi M, Sharma VK. 2006. Treatment of enteric fever in children on the basis of current trends of antimicrobial susceptibility of Salmonella enterica serovar typhi and paratyphi A. Indian J. Med. Microbiol. 24: 101-106. http://dx.doi.org/10.4103/0255 -0857.25182.
37. Morosini MI, Garcia-Castillo M, Coque TM, Valverde A, Novais A, Loza E, Baquero F, Canton R. 2006. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob. Agents Chemother. 50:2695-2699. http: //dx.doi.org/10.1128/AAC.00155-06.